Advertisement

Topics

sanofi-aventis/Bristol-Myers Squibb Partnership Company Profile

07:53 EDT 19th September 2017 | BioPortfolio


News Articles [1705 Associated News Articles listed on BioPortfolio]

Bristol-Myers Squibb and QIAGEN collaborate

Bristol-Myers Squibb Company and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as  predictive or prognos...

Bristol-Myers To Sell Manufacturing Facility In Swords, Ireland

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and SK Biotek Co. Ltd. announced a purchase agreement to sell Bristol-Myers Squibb's small molecule active pharmaceutical ingredient ma...

Research Analysts' Weekly Ratings Changes for Bristol-Myers Squibb

A number of firms have modified their ratings and price targets on shares of Bristol-Myers Squibb recently: 7/27/2017 - Bristol-Myers Squibb was given a new $60.00 price target on by analysts at Piper...

Bristol-Myers Squibb To Acquire IFM Therapeutics

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and IFM Therapeutics announced the companies have signed an agreement under which Bristol-Myers Squibb will acquire all of the outstand...

Bristol-Myers Squibb to Take Part in UBS Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in the UBS Global Healthcare Conference on Monday, May 22, 2017, in New York. Murdo Gordon, executive vice president...

Bristol-Myers Squibb Completes Acquisition of IFM Therapeutics

NewsBristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics. The transaction includes full rights to IFM’s preclinical STING and NLRP3 agonist programs focused on enhanci...

Bristol-Myers & Seattle Genetics To Evaluate Combination Of Opdivo And ADCETRIS

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and Seattle Genetics, Inc. (SGEN) announced a collaboration agreement to evaluate the combination of Bristol-Myers Squibb's immunothera...

Bristol-Myers Squibb to Acquire IFM Therapeutics, Strengthening its Oncology Pipeline Focus on Innate Immunity

NEW YORK & BOSTON–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and IFM Therapeutics (IFM) announced today that the companies have signed a definitive agreement under which B...

PubMed Articles [259 Associated PubMed Articles listed on BioPortfolio]

Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema.

To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME).

A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials.

A systematic review of the Bristol-Myers Squibb normal healthy volunteers (NHVs) database identified phase 1 trials that included NHVs administered placebo with the aim of characterizing normal inter-...

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.

On December 22, 2014, the U. S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (OPDIVO®, Bristol-Myers Squibb) for the treatment of patients with unresectable or metasta...

Update: Temporary Total Depletion of U.S. Licensed Yellow Fever Vaccine for Civilian Travelers Addressed by Investigational New Drug Use of Imported Stamaril Vaccine.

Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-VAX) licensed in the United States, has announced that their stock of YF-VAX is totally depleted as of July 24, 2017. YF-VAX for c...

Partnership agreements less likely among young gay and bisexual men in Australia ? data from a national online survey of gay and bisexual men.

Background: How gay and bisexual men (GBM) establish partnership agreements may be affected by several factors, including age. The ability to communicate with a partner about sexual agreements has imp...

Clinical Trials [295 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single,...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg

The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single,...

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Companies [739 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb & Sanofi-aventis

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the l...

sanofi-aventis/Bristol-Myers Squibb Partnership

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

More Information about "sanofi-aventis/Bristol-Myers Squibb Partnership" on BioPortfolio

We have published hundreds of sanofi-aventis/Bristol-Myers Squibb Partnership news stories on BioPortfolio along with dozens of sanofi-aventis/Bristol-Myers Squibb Partnership Clinical Trials and PubMed Articles about sanofi-aventis/Bristol-Myers Squibb Partnership for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of sanofi-aventis/Bristol-Myers Squibb Partnership Companies in our database. You can also find out about relevant sanofi-aventis/Bristol-Myers Squibb Partnership Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record